The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

St. Jude to Open Grad School for Biomedical Sciences

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ST. JUDE CHILDREN’S RESEARCH HOSPITAL has received a unanimous vote of approval from the Tennessee Higher Education Commission for the opening of a new graduate school of biomedical sciences.

Stephen White, a faculty member in the St. Jude Department of Structural Biology, will serve as dean of the graduate school. The school will be located in the Marlo Thomas Center for Global Education and Collaboration, and will welcome the inaugural class in fall 2017.

“The graduate school will play an important role in our research efforts to advance cures for pediatric catastrophic diseases,” said James Downing, St. Jude president and CEO, “Talented graduate students are a creative and energetic force that will contribute to the kind of innovation required for progress against cancer and other life-threatening diseases. These students will ask the unexpected questions, challenge fundamental assumptions and will help tackle the most difficult scientific problems.”

Students will also interact with the neighboring University of Tennessee Health Science Center and Le Bonheur Children’s Hospital.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account